1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,264 | 1,386 | 30.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MOLECURE Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CO.DON | 0,015 | 0,00 % | EQS-AFR: CO.DON AG i.l.: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: CO.DON AG i.l.
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
CO.DON AG i.l.: Vorabbekanntmachung über die... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,102 | -10,03 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT) | ||
| IMMATICS | 9,460 | -1,41 % | TD Cowen initiates Immatics stock coverage with buy rating | ||
| ALDEYRA | 1,310 | +1,55 % | Aldeyra Therapeutics, Inc.: Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London | Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced... ► Artikel lesen | |
| MEDIFAST | 9,130 | -2,46 % | Medifast: OPTAVIA Premieres Second Docuseries Episode "Health by Design: Spain" Exploring Metabolic Health and Longevity | Thousands of Independent Coaches Gather Nationwide to Discuss Solutions to America's Metabolic Health Crisis Medifast (NYSE: MED), the health and wellness company known for its science-backed... ► Artikel lesen | |
| PHARMING | 1,440 | +2,35 % | Pharming Group N.V.: Pharming Group to report first quarter 2026 financial results and provide business update on May 7 | Leiden, the Netherlands, April 23, 2026: Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,516 | +1,40 % | Coherus Oncology, Inc.: Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update | - LOQTORZI net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 - - Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 - - $172.1... ► Artikel lesen | |
| ORUKA THERAPEUTICS | 58,00 | -0,85 % | Oruka Therapeutics, Inc.: Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis | ORKA-001 achieved 63.5% (40/63) PASI 100 at Week 16 Favorable safety profile consistent with the IL-23p19 class Updated Phase 1 PK/PD data continue to support the potential for once-yearly dosing... ► Artikel lesen | |
| INNOVIVA | 19,600 | -1,01 % | Cantor Fitzgerald reiterates Innoviva stock rating on royalty strength | ||
| ARMATA PHARMACEUTICALS | 8,900 | +9,20 % | Pfizer-Führungskraft verstärkt Verwaltungsrat von Armata Pharmaceuticals | ||
| LIQUIDIA | 33,070 | +1,13 % | Liquidia Technologies, Inc.: Liquidia Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Achieved YUTREPIA net product sales of $148.3 million for the full year 2025 with $90.1 million in the fourth quarterMore than 3,600 unique prescriptions received and 2,900 patients treated to date... ► Artikel lesen | |
| SYNDAX PHARMACEUTICALS | 17,815 | +0,79 % | Syndax Pharmaceuticals, Inc.: Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | - Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 - - Revuforj- (revumenib) net revenue of $44.2 million in 4Q25, a 38% increase vs 3Q25, and $124.8 million in FY2025 - - Niktimvo... ► Artikel lesen | |
| DBV TECHNOLOGIES | 3,584 | +0,67 % | DBV Technologies S.A.: Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026 | Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026
(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)
Market... ► Artikel lesen | |
| BRAINSTORM CELL THERAPEUTICS | 0,673 | -100,00 % | BrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update | Strategic $2.0 million post year-end financing and re-rating of BCLI shares underscore market confidence
Company highlights durable long-term survival in Expanded... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 4,625 | +2,21 % | SIGA Technologies Inc.: SIGA to Host Business Update Call on May 7, 2026, Following Release of First-Quarter 2026 Financial Results |
Das Unternehmen MOLECURE SA kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -3,98 % bei einem Aktienkurs von 1,254 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MOLECURE SA finden Sie auf Wallstreet Online.